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Chapter 1.  Introduction 
1.1.  Production of biopharmaceuticals 
Biopharmaceuticals are now become one of main approach to therapy of cancer, 
rheumatism and other various therapeutic area (1). More than half of top ten sale 
pharmaceutical drug are biopharmaceuticals produced in bioprocess using genetically 
modified cells or microorganism (2). There are two strategies to obtain production 
capability, one is scale-out, and another is scale-up strategy. Scale-out is a method of 
increasing production capacity by increasing the number of production equipment. Scale-
up is a method of increasing the volume of production in a single manufacturing 
opportunity by increasing the capacity and scale of production equipment. Each method 
has its advantages, but in many cases, a combination of both methods seems to have 
effectiveness and flexibility. Thus, bioprocess scale-up of biopharmaceuticals production 
is important to produce drug substance keeping productivity, quality and reducing cost of 
goods. The types of biopharmaceuticals include protein drugs, antibody-drug conjugate 
(ADC), Chimeric Antigen Receptor-T Cell Therapy (CAR-T), and cell therapies. Table 1 
shows example of biopharmaceuticals. 
 
Table 1 Example of Modality and indication of biopharmaceuticals*1 
Modality Product name Indication Launch 
























Gene therapy ZOLGENSMA® Spinal muscular atrophy 2019 
*1 This table was created by the author based on the Nikkei Bio yearbook.  
*2 ALL: Acute Lymphoblastic Leukemia 
*3 DLBCL: Diffuse Large B-Cell Lymphoma 
 
The monoclonal antibody (Mab) is one of protein drug, which has the largest number of 
launches and developments in the market. Mabs have often been produced by batch 
culture or fed-batch culture process of CHO cells. In the fed-batch culture production 
process, it was reported that Mab concentration was reached to 10 g/L in harvest (3, 4, 5, 
6, 7). 
This shows that productivity is increased more than 10 times at least in 30 years (8). In 
addition, the perfusion culture process, which has been attracting attention as one of the 
new type production processes, has been developed in industry. In this perfusion process, 
the concentration of cells in the process is reported to be 10 times higher than that in fed-
batch culture, and the concentration of antibodies is reported to be 10 times higher. 
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Improvements of cell culture and cell line developments are recognized as the great 
contribution for these progresses. Also, accompanying improvement of productivity, i.e., 
quality assurance, is required with increase of productivity (9). 
 
 
1.2.  Scale-up method of bioreactor for CHO cell  
In addition, production scales are expected to be increased with the development stage of 
pharmaceutical pipeline progresses and the manufacturing site changes. There are several 
stages of pharmaceutical development, including toxicity studies in animals, clinical trials 
for human use, and commercialization. Table 2 summarized pharmaceutical product 
development stage. Quality equivalence should be kept during these development stage 
and scale-up process to ensure efficacy and toxicity consistency. 
 





















Scale Minimum Small Medium Large - 
 
In order to ensure such quality equivalence, additives to various culture media have been 
reported (10, 11). Although these methods control the physical properties of 
biopharmaceuticals themselves, there are various studies for cell culture parameters to 
control the quality of protein drugs. Various cell culture parameters, such as pH and 
temperature are known to affect product quality such a glycan profile, aggregation content 
(9, 12), and optimal culture conditions have been investigated using various cell lines and 
medium. It is also well known that the dissolved carbon dioxide concentration (dCO2) 
also affects the product quality (13). However, since CO2 was released from cells by 
metabolism of TCA cycle, it is difficult to exactly control the dCO2 during cell culture 






Figure 1 Diagram of the behavior of carbon dioxide in a bioreactor. Red arrow shows 
carbon dioxide release from cells. Blue arrow shows carbon dioxide stripping by bubble 
and release to over ray in the bioreactor. 
  
On the other hands, Feng Li also reported the importance of the construction of proper 
scale-down model (14). To solve the scale -up problem, it is important to construct the 
simulated scale-down model because to it is expensive and time-consuming to use large-
scale culture for investigation. The trend of dCO2 during the cell culture process is related 
to the parameter kLa(CO2) which is dependent on shape of the bioreactor and medium 
composition. It is also known that kLa(CO2) varies depending on the scale of the 
bioreactor, agitation and the aeration conditions (15, 16). 
 
 
1.3.  Summary of my research 
In this thesis, I compare the scale up factors obtained by calculation and by experiment. I 
focused on Power per unit volume (P/V) value for a scale-up factor obtained from the 
calculation (Chapter 2), and mixing time and kLa for a scale-up factor obtained from the 
experimental data (Chapter 4). Mixing time and the kLa ratio calculated by kLa(O2) and 
kLa(CO2) was evaluated for the scale up of bioreactor (Chapter 3). kLa(O2) was related to 
aeration rate to control dissolved oxygen concentration (DO). Stripping of CO2 from 
medium is related to kLa(CO2) and aeration rate. If the kLa ratio is kept constant, the time 
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course of dCO2 during cultivation could be expected to be similar. I adopted P/V for the 
scale-up factor of a SS bioreactor with similar shape. The agitation condition was 
determined by P/V, and the other scale-dependent condition, i.e., feed ratio of feed 
medium, medium volume which was determined by the scale ratio. These other 
conditions were determined based on the previous experiments. Recently, single-use 
reactors are commonly used for middle-scale (from several hundreds to thousands liter 
scale) production of therapeutic antibodies. Various types of single-use bioreactors are 
provided by various companies and these designs are not the same. However, the 
calculation of P/V of single-use bioreactor for scale-up is not easy, because the detail 
design and size of impeller and vessel are not open for users. Therefore, scale-up 
methodology using scale-up factor based on experimental data, such as kLa ratio, was 
necessary for commercial-based production. In this thesis, the agitation and the aeration 
conditions were determined on the basis of calculated kLa ratio (Figure 2). I achieved the 
scale-up methodology using both calculation–based and experimental data-based method 
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Figure 2 Experimental strategy for this thesis. Developed process in 200-L scale SS 
bioreactor was scaled-up to 2000-L scale SS bioreactor and single-use bioreactors (200-
L and 1000-L scale).  
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Chapter 2.  Scale up based on Power per unit volume  
2.1.  Introduction 
In the microbial fermentation for food, drink, and pharmaceutical production, scale-up 
has been studied in various ways. P/V, Reynolds number, and agitator tip speed were used 
as the scale-up indicator for these studies. The tip speed of the impellor is known to be 
associated with shear stress to the cells. Although this is a considerable point when scaling 
up, in this thesis, it was not treated as a direct scale up factor. The Reynolds number is an 
index of the flow condition of the liquid phase. In the previous study, in case the Reynolds 
number was more than 10000 in the agitation tank, the flow is considered to be turbulent. 
It was confirmed that the flow was turbulent in all the agitation conditions of the 
bioreactor evaluated in this thesis (data not shown). P/V represents the amount of energy 
consumption per unit volume and has been calculated using an equation that is estimated 
from electricity consumption data. In this thesis I focused on the mixing and gas exchange 
conditions in the bioreactor. As an evaluation of mixing condition, I attempted to scale up 
the process of CHO cells culture using the P/V formula. In this chapter, scale-up study on 





2.2.  Materials and Methods 
2.2.1.  Power per unit volume calculation 
Power per unit volume (P/V) was calculated for 2000-L scale bioreactor and 200-L scale 
stainless steel (SS) bioreactor for scale-up.  
P/V=  (1) 
where Np (-) is power number explained by Nagata (17), ρ (kg m-3) is degree of density 
of water, N (rotation per seconds) is agitation speed, Di (m) is impeller diameter, V (m3) 
is estimated maximum volume in fed-batch culture process. During fed-batch culture, 
culture volume continuously increases by the addition of feed medium. In this P/V 
calculation, I set V to maximum volume at the end of cultivation which is calculated from 
the time course of our previous 2-L scale fed-batch culture using glass vessel. 
 
2.2.2.  Cell line and medium 
Cell lines A expressing Mabs A was established using CHOK1SV cells as the host cell 
and the GS Gene Expression System provided by Lonza Biologics (Slough, Berkshire, 
UK). This cell line was selected in CD CHO medium (Life Technologies, Carlsbad, CA, 
USA) containing methionine sulfoximine. Chemically defined basal medium was 
developed for the fed-batch process by modifying the CD CHO medium with in-house 
proprietary supplements. This protein-free, chemically defined feed media developed in-
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house were used for the fed-batch culture for this thesis. 
 
2.2.3.  Fed-batch culture 
Fed-batch cultures were performed using IgG-producing CHO cell line A. In-house 
serum-free basal and feed medium were used in this thesis. Agitation was kept at speed 
which was determined to show the expected power per unit volume. The temperature was 
kept at 37ºC. The pH was controlled by pure CO2 sparging and by the addition of 1.0M 
sodium carbonate. DO was controlled at 50% air saturation by aeration to headspace and, 
oxygen and air mixed gas aeration from sparger.  Small amount of sample was taken 
from reactor and DO, dCO2 and pH were measured by a blood gas analyzer (Rapidlab 
348 blood gas analyzer (Bayer Corp., MA, USA)). Cell viability and viable cell density 
were measured by Vi-CELL XR (Beckman Coulter, CA, USA). Glucose and lactate 
concentrations in the supernatant were determined with a BF-5 bioanalyzer (Oji Scientific 
Instruments, Hyogo, Japan). After centrifugation, Mab concentration was measured using 
an HPLC system (Waters/mS, USA) with a UV detector and a POROS PA affinity column 
(Applied Biosystems/mA, USA). Specific growth and production rates were calculated 




2.3.  Results 
2.3.1.  Evaluation of power per unit volume calculation of Stainless Steel (SS) 
bioreactor 
In order to scale up from 200-L bioreactor to 2000-L bioreactor, P/V of each bioreactor 
was calculated. For calculation, estimated maximum volume V in fed-batch culture 
process was used in each scale. The agitation speed in the 200-L bioreactor was set for 1 
m/sec tip speed. For 2000-L SS bioreactor, the control agitation speed  was determined 
by the condition showing similar P/V value to 200-L SS bioreactor. P/V in control 
condition of 200-L was 82 W/m3, and P/V in control condition of 2000-L was 84 W/m3, 
respectively.  
 
2.3.2.  Fed-batch culture result comparing SS 200-L to 2000-L scaled up based on 
power per unit volume calculation 
In order to evaluate the scale-up process by agitation condition determined by P/V, fed-
batch cultures of CHO cell line A using 200-L and 2000-L scale SS bioreactor were 
carried out. Fed-batch culture was continued to 16 days. Sampling was taken daily during 
the culture period to measure viable cell density, viability, glucose and lactate 
concentrations (data not shown), and Mab concentration. Figure 3 shows time course of 
Mab concentration, viable cell density, viability, and dCO2. Mab concentration, viable 
cell density, viability showed the similar trend between 200-L and 2000-L cultivations. 
The maximum viable cell density was about 20 x 106 cells/mL on both scales. The 
14 
 
viability gradually decreased after the 12th day of culture. The Mab concentration reached 
about 6 g/L at the time of harvest. dCO2 shifted around 60 mmHg in the 200-L scale 
throughout the culture period, but it was kept at around 80 mmHg on the 2000-L scale. 
dCO2 tended to be higher on the 2000-L than that on 200-L cultivation. Specific Mab 
production rate was 33  0.6 pg cell-1 day-1 in 200-L scale fed-batch culture, and 33  0.2 
pg cell-1 day-1 in 1000-L scale fed-batch culture, respectively. Specific growth rate during 
day 1 to day 7 were 0.021 0.003 h-1 in 200-L scale fed-batch culture, and 0.023 0.001 
h-1 in 2000-L scale fed-batch culture, respectively. Even the different dCO2 during 











Figure 3 Time course of cell line A cultivation in 2000-L scale SS bioreactor with P/V 
based agitation condition. A: Mab concentration, B: Viable cells density, C: Viability, D: 
dCO2. Symbols are 200-L scale (closed circle) and 2000-L scale (closed square). 
 
 
2.4.  Discussion 
In the similarly-shaped 200-L and 2000-L scale bioreactor, agitation conditions were 
determined, that showed P/V of 82 W/m3 and 84 W/m3, respectively. The stainless steel 
(SS) bioreactor was easy to calculate the P/V value, because bioreactor was designed by 
ourselves. This is an advantage of the stainless steel (SS) bioreactor. In the 2000-L scale, 
the concentration of dissolved CO2 tended to be higher than those in 200-L scale after day 



























































































the amount of aeration to remove dissolved carbon dioxide from the culture medium 
between 200-L and 200-L aerations. The aeration rate per unit volume of culture medium 
was higher on the 200-L scale (Data not shown). The cell growth and viability of cells 
that were affecting by dCO2 during cell culture process were similar in both scales in this 
thesis. However, in the larger bioreactor than 2000-L scale, any further dCO2 
accumulation may has negative impact to cell growth. The tip speed was higher on the 
200-L scale than that on the 2000-L scale. The shear stress on agitation speed in this 200-
L scale had no effect on cell growth and antibody productivity. For the further analysis of 





Chapter 3.  Mixing time and kLa evaluation for bioreactors 
3.1.  Introduction 
In this chapter, for the performance evaluation of bioreactors mixing time study and kLa 
study were reported. In mixing time study, various agitation conditions were evaluated in 
view of mixing performance. In kLa study, kLa ratio was evaluated in various agitation 
conditions between appropriate agitation range for SS 2000-L scale bioreactor and single 
use bioreactors in view of gas exchange conditions.  
The mixing time is the time it takes for the bioreactor to become from non-uniform to 
95% uniform (18). In a scale of less than 2,000 L cultivation for CHO cells, the mixing 
time was reported to be within approximately one minutes. A formula for estimating the 
mixing time in a tank with the following conditions is also reported(16, 17, 19). 
1. Liquid height and diameter are 1:1 
2 There are four baffle plates, and the ratio of plate width and tank diameter range are 
from 1:10 to 1:12. 
3 Impellor blades of 1/3 to 1/2 of the tank diameter 
4 The position of the impellor blade is 1/3 to 1/4 of the height from the bottom of the tank. 
In this thesis, it was thought that all of the above conditions may not be suitable for SS 
bioreactors. For single use bioreactor, at least one of condition is not suitable. Then, I 
decided to perform measurements of the mixing time. 
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In the field of chemical engineering, kLa is an index that comprehensively expresses the 
gas exchange capacity of between the gas and liquid phases in a vessel. In bioprocess for 
CHO culture, pure oxygen is supplied in the bioreactor for supplying oxygen to the cells. 
At the same time, the bubbles remove the carbon dioxide from the culture medium. 
Therefore, in the higher kLa (O2) condition, the less oxygen is supplied, and the less 
carbon dioxide is removed. As the kLa (O2) increases, the kLa (CO2) also increases. 
However, the sensitivity of the change of kLa to the airflow rate change is different. 
Consequently, I considered that it important to keep the ratio of kLa (O2) to kLa (CO2) 
below a certain level in order to remove dissolved carbon dioxide. Therefore, the kla ratio 
of oxygen to carbon dioxide was evaluated. 
 
3.2.  Materials and Methods 
3.2.1.  Mixing time 
Mixing time in the bioreactor was evaluated by pH measurement. A calibrated pH sensor 
(Mettler toledo, OH, USA) was installed in the bioreactor, and purified water was filled 
into a bioreactor at room temperature and agitated under various bioreactor scale and 
agitation speed. After confirming the uniform mixing in the bioreactor by observation, 5 
M NaOH (Merck KGaA, Darmstadt, Germany) was shortly added from the top of the 




3.2.2.  kLa measurement and evaluation 
Both kLa (O2) and kLa (CO2) were measured by dynamic gassing-out method (20) using 
phosphate buffered saline (PBS) instead of serum-free medium. In brief, PBS (T900, 
Takara bio, Shiga, Japan) diluted in purified water to 50% was filled and kept at 37 ºC in 
each scale bioreactors. In kLa(O2) study, DO sensor (METTLER TOLEDO, OH, USA) 
was used for DO measurement. DO sensor was calibrated in 100% on air saturation 
condition. Nitrogen gas was sparged into the bioreactor until DO was decreased and 
became stable, and then calibrated to 0%. After 0% calibration, Nitrogen gas in head 
space of bioreactor was replaced to air. Agitation and air-sparge were started and then DO 
was recorded until saturated by air. The kLa (O2) was calculated according to below 
equation (2). 
     (2) 
where [DO]s is saturated value (% air saturated), [DO]0 is value in t=0 (min), and [DO]t 
is value at elapsed time t. kLa was calculated as a slope of the linear plot of ln([DO]s-
[DO]0)-ln([DO]s-[DO]t) against t. 
In kLa(CO2) study, dCO2 sensor (METTLER TOLEDO, OH, USA) was used for dCO2 
measurement. Pure CO2 gas was sparged into the bioreactor with PBS until dCO2 value 
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became stable, and then dCO2 sensor (METTLER TOLEDO, OH, USA) was calibrated 
to 100%. After 100% calibration, CO2 gas in head space of bioreactor was replaced to air. 
Agitation and air sparge were started and then dCO2 was recorded until fully dropped and 
became stable. From recorded data, kLa(CO2) was according to below equation (3). 
    (3) 
where [dCO2]s is saturated value, [dCO2]0 is value in t=0, and [dCO2]t is value at elapsed 
time t. kLa was calculated as a slope of the linear plot of ln([dCO2]s-[dCO2]0)-ln([dCO2]s-
[dCO2]t) against t. 
 







   (4) 
 
3.3.  Results 
3.3.1.  Mixing time study 
The characteristics of the bioreactor were also evaluated by experimental data for scale-
up. The mixing time was analyzed using pH measurement. Figure 4 summarized the 
results of mixing time study. The mixing time of the 200-L scale SS bioreactor was 21 
seconds under the control agitation condition. In the 2000-L SS bioreactor, mixing time 
was 40 seconds under the agitation condition which was determined based on P/V. At this 
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agitation condition of the 2000-L bioreactor, the cell growth, specific Mab production rate 
was similar to those of the 200-L scale. Specific Mab production rate were 33  0.6 pg 
cell-1 day-1 in 200-L scale fed-batch culture and 33  0.2 pg cell-1 day-1 in 2000-L scale 
fed-batch culture. And Specific growth rate during day 1 to day 7 were 0.021 0.003 h-1 
in 200-L scale fed-batch culture and 0.023 0.001 h-1 in 2000-L scale fed-batch culture. 
It was presumed that mixing time did not affect the cell growth and Mab productivity. 
The mixing time of single-use bioreactors from vendor A, B, and C were also evaluated. 
Vendor A provided 200-L scale and 1000-L scale, vendors B and C provided the 200-L 
scale. On the 200-L scale, the mixing time for vendor A reactor was about 30 seconds 
between 45 rpm and 100 rpm, the time for vendor B reactor was about 35 seconds at more 
than 100 rpm, and the time for vendor C reactor was less than 35 seconds at more than 
210 rpm. From the results of mixing time and comparison with a SS bioreactor, it was 
estimated that the appropriate agitation range for 200-L single-use reactor was 45 rpm or 
more for vendor A, 100 rpm for vendor B and 210 rpm or more for vender C, respectively.  
For the vendor A 1000-L scale single-use bioreactor, the mixing time was around 60 
seconds under between 25 and 50 rpm agitation condition, but it was less than 30 seconds 
under more than 65 rpm. Based on this result, it seems that appropriate agitation condition 
is more than 65 rpm in this 1000-L scale bioreactor from viewpoint of mixing time. From 
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the result of scale-up in SS bioreactor based on P/V, under 40 second mixing time may 
not affect the cell growth and productivity of 200-L and 2000-L scale fed-batch culture 
using cell line A. It's supposed that the suitable agitation condition (40 second mixing 
time) should exist between 50 rpm and 65 rpm. 
Figure 4 Mixing time in various bioreactor. Mixing time was evaluated under various 
agitation conditions at SS bioreactors and single-use bioreactors. 
 
3.3.2.  kLa study in SS bioreactor 
The appropriate agitation condition was determined from the investigation of mixing time. 
Agitation speed and aeration condition which showed the similar kLa ratio as that of 200-
L scale SS bioreactor were used for study. Determined conditions are, with the 0.012 vvm 
head-space aeration, and either 0.0085 vvm or 0.035 vvm the sparge rate in a 200-L scale 
bioreactor. For 2000-L scale, the head-space aeration is 0.012 vvm and the sparge rate is 



















































































































































































































In 2000-L scale SS bioreactor, kLa(O2) and kLa(CO2) were measured at agitation speed 
determined based on P/V result. As shown in Table 3, the kLa ratio in 2000-L bioreactor 
was lower than that in 200-L bioreactor at the agitation speed which was previously 
determined condition showing the similar P/V. kLa(O2) of 2000-L scale bioreactor was 
37% higher than kLa (O2) of 200-L scale bioreactor under control agitation condition. 
kLa(CO2) of 2000-L scale bioreactor was 6% lower than kLa(CO2) of 200-L scale 
bioreactor under control agitation condition. It was suggested that CO2 tends to 
accumulate in the 2000-L scale bioreactor medium under control agitation condition. kLa 
changes with depending on agitation condition. In order to evaluate the effect of agitation 
condition, the trend of kLa ratio when changing the agitation speed on the 2000-L scale 
was evaluated. Agitation condition presumed to be similar kLa of dCO2 to the 200-L scale 
was determined as a result of evaluation by sensitivity study of agitation speed. Agitation 
speed was changed from minus 6 rpm of control to plus 1 rpm of control condition. As a 
result, kLa ratio was decreased with the increase of agitation speed of 2000-L scale. The 
reason of this was that kLa(O2) is more sensitive than kLa(CO2) by change of agitation 
speed in 2000-L scale. Matsunaga also reported about the relationship that of culture 




Table 3 kLa(O2), kLa(CO2) and kLa ratio in SS bioreactors. 




 0.0085 (vvm)      0.015 (vvm) 
SS 200-L Control* 1.57 - 
SS 2000-L 
Control-6 (rpm) 1.37 - 
Control-5 (rpm) 1.44 - 
Control-4 (rpm) 1.54 2.78 
Control-3 (rpm) 1.68 - 
Control-2 (rpm) 1.84 - 
Control-1 (rpm) 2.09 - 
Control* 2.15 4.05 
Control+1 (rpm) 2.80 - 




 0.0085 (vvm)      0.015 (vvm) 
SS 200-L Control* 0.83 - 
SS 2000-L 
Control-6 (rpm) 0.67 - 
Control-5 (rpm) 0.69 - 
Control-4 (rpm) 0.70 1.12 
Control-3 (rpm) 0.72 - 
Control-2 (rpm) 0.77 - 
Control-1 (rpm) 0.81 - 
Control* 0.78 1.24 
Control+1 (rpm) 0.83 - 




 0.0085 (vvm)      0.015 (vvm) 
SS 200-L Control* 0.53 - 
SS 2000-L 
Control-6 (rpm) 0.49 - 
Control-5 (rpm) 0.48 - 
Control-4 (rpm) 0.46 0.40 
Control-3 (rpm) 0.43 - 
Control-2 (rpm) 0.42 - 
Control-1 (rpm) 0.39 - 
Control* 0.36 0.31 
Control+1 (rpm) 0.30 - 






3.3.3.  kLa study in single-use bioreactor 
In the single-use bioreactor, the kLa(O2), kLa(CO2) and kLa ratios were similarly evaluated 
within the range determined by previous mixing time study. As shown in Table 4, under 
the condition of 100 rpm, the 200-L scale of vendor A with 0.0085 vvm (0.56) and 0.035 
vvm (0.46) air sparging and the 200-L scale of vendor B with 0.035 vvm (0.42) air 
sparging showed the same kLa ratio as that of SS 200-L bioreactor (0.53 in 0.0085 vvm 
and 0.43 in 0.035 vvm) .  
Vendor B single-use bioreactor have two types of spargers, i.e., sinter pipe and drilled 
hole. In the case of sparge with sinter pipe at 0.035 vvm and 150 rpm, kLa(O2) increased 
1.5 times (8.30 h-1 on drilled hole sparger and 12.02 h-1on sinter pipe sparger) comparing 
with drilled hole sparger under the same sparging condition (0.035vvm and 150rpm), but 
kLa(CO2) with sinter pipe sparger (2.45 h
-1) was almost the same with drilled hole sparger 
(2.35 h-1). Therefore, the kLa ratio with sinter pipe sparger become lower than that in 
drilled hole sparger. 
The agitation condition for vendor C single-use bioreactor was determined for 210 rpm 
or more based on the previous mixing time study. However, at more than 210 rpm 
condition, I could not find the agitation condition showing the similar kLa ratio of 200L 
SS bioreactor (between 0.0085 vvm to 0.0035 vvm). To seek the condition showing 
similar kLa ratio to 200-L SS bioreactor, kLa(O2) and kLa(CO2) were measured under the 
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condition of additional pure nitrogen gas sparging in 0.001, 0.002 and 0.005 vvm at 210 
rpm, and the kLa ratio was evaluated. Nitrogen gas sparging decreased kLa(O2), because 
O2 concentration in supplied gas to bioreactor was decreased by nitrogen gas sparging, 
and increased kLa(CO2) because total amount of supplied gas was increased. When 
nitrogen gas sparging rate was 0.001 vvm, it showed the same kLa ratio as 200 L SS 
bioreactor in conditions of both 0.0085 vvm air sparging and 0.035 vvm air sparging. It 
was concluded that 210 rpm agitation and nitrogen aeration 0.001 vvm nitrogen aeration 
are recommended for the fed batch cultivation using vendor C single-use bioreactor. 
Table 4 kLa and kLa ratio in single-use bioreactors. 
kLa(O2) (h-1) 
Agitation condition 
/nitrogen gas sparge 
Air sparge 
0.0085 (vvm)        0.035 (vvm) 
SS 200-L Control* / NA 1.57 4.06 
Vendor-A 200-L 
(Open pipe sparger) 
25 (rpm) / NA 0.29 0.83 
45 (rpm) / NA 0.37 0.92 
100 (rpm) / NA 1.45 3.69 
Vendor-A 1000-L 
(Open pipe sparger) 
50 (rpm) / NA - 5.21 
60 (rpm) / NA 2.35 7.85 
70 (rpm) / NA 3.95 11.09 
80 (rpm) / NA 6.45 13.50 
Vendor-B 200-L 
(Drilled hole sparger) 
100 (rpm) / NA - 4.18 
125 (rpm) / NA - 6.73 
150 (rpm) / NA 2.33 8.30 
Vendor-B 200-L 
(sinter pipe sparger) 
150 (rpm) / NA - 12.02 
Vendor-C 200-L 
(Drilled hole sparger) 
210 (rpm) / NA 2.97 10.65 
220 (rpm) / NA 3.28 10.95 
250 (rpm) / NA 4.64 12.12 
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210 (rpm) / 0.001 vvm 2.80  10.65  
210 (rpm) / 0.002 vvm 2.50  10.48  




/nitrogen gas sparge 
Air sparge 
0.0085 (vvm)        0.035 (vvm) 
SS 200-L Control* / NA 0.83 1.76 
Vendor-A 200-L 
(Open pipe sparger) 
25 (rpm) / NA - - 
45 (rpm) / NA 0.27 0.76 
100 (rpm) / NA 0.81 1.69 
Vendor-A 1000-L 
(Open pipe sparger) 
50 (rpm) / NA - 2.40 
60 (rpm) / NA 0.85 2.80 
70 (rpm) / NA 0.97 3.31 
80 (rpm) / NA 1.04 3.78 
Vendor-B 200-L 
(Drilled hole sparger) 
100 (rpm) / NA - 1.77 
125 (rpm) / NA - 1.99 
150 (rpm) / NA - 2.35 
Vendor-B 200-L 
(sinter pipe sparger) 
150 (rpm) / NA - 2.45 
Vendor-C 200-L 
(Drilled hole sparger) 
210 (rpm) / NA 1.23 4.26 
220 (rpm) / NA 1.32 4.38 
250 (rpm) / NA 0.87 2.52 
210 (rpm) / 0.001 vvm 1.39  4.40  
210 (rpm) / 0.002 vvm 1.52  4.53  




/nitrogen gas sparge 
Air sparge 
0.0085 (vvm)       0.035 (vvm) 
SS 200-L Control* / NA 0.53 0.43 
Vendor-A 200-L 
(Open pipe sparger) 
25 (rpm) / NA - - 
45 (rpm) / NA 0.72 0.83 
100 (rpm) / NA 0.56 0.46 




(Open pipe sparger) 
60 (rpm) / NA 0.36 0.36 
70 (rpm) / NA 0.24 0.30 
80 (rpm) / NA 0.16 0.28 
Vendor-B 200-L 
(Drilled hole sparger) 
100 (rpm) / NA - 0.42 
125 (rpm) / NA - 0.30 
150 (rpm) / NA - 0.28 
Vendor-B 200-L 
(sinter pipe sparger) 
150 (rpm) / NA - 0.20 
Vendor-C 200-L 
(Drilled hole sparger) 
210 (rpm) / NA 0.41 0.40 
220 (rpm) / NA 0.40 0.40 
250 (rpm) / NA 0.19 0.21 
210 (rpm) / 0.001 vvm 0.50 0.41 
210 (rpm) / 0.002 vvm 0.61 0.43 
210 (rpm) / 0.005 vvm 1.02 0.48 
*Agitation speed at SS 200-L was not be shown because of company’s confidential information. 
 
3.3.4.  Discussion 
The mixing time tended to be shortened with increase of the agitation speed in all the 
bioreactor. However, there was no linear relationship between mixing time and agitation 
speed. A linear relationship equation was not reported in the previous study. As a mixing 
time is complicatedly affected by the shape of the bioreactor, the shape and number of 
impellors, and other factors, it is difficult to establish an exact prediction formula. 
Experiments in a 2000 L scale SS bioreactor showed that the mixing time was extremely 
long under the agitation conditions of Control-16. It was visually confirmed that the 
movement of the liquid phase was slow and insufficient for mixing during measurement. 
It was suggested that the performance of the bioreactor could be extremely decreased 
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without a certain number of agitations condition. 
In all bioreactors, kLa increases in both oxygen and carbon dioxide with increase of the 
agitation speed. From the comparison between Vendor-B sinter pipe and drilled hole 
sparger, it was shown that the both of kLa increased by the small size of the bubbles. If 
bubbles with diameters of 20 m and 2 mm, respectively, are supplied at the same airflow 
rate, the total contact surface area of 20 m bubbles between the bubbles and the liquid 
is 100 times larger than that of 2 mm. However, the kLa(O2) and kLa(CO2) was only 1.4 
and 1.1 times larger, respectively. The results suggest that factors other than surface area 
may be largely responsible for the increase of kLa. The sensitivity of kLa(O2) and kLa(CO2) 





Chapter 4.  Scale up based on kLa ratio  
4.1.  Introduction 
In this chapter, fed-batch culture results of the process based on kLa ratio were reported. 
In Chapter 3, appropriate cell culture conditions in kLa ratio was found in SS bioreactor 
and SUBs. Summary of these cell culture conditions was shown in Table 5. 
 
Table 5 Summary for cell culture condition based on kLa ratio 




Stainless-steel 200-L Control agitation 
condition 
NA 





Vendor A 200-L 100 rpm NA 
Vendor B 200-L 100 rpm NA 
Vendor C 200-L 210 rpm 0.001 vvm 





4.2.  Materials and Methods 
4.2.1.  Cell line and medium 
Two recombinant CHO cell lines were used in this thesis. Cell lines A and B expressing 
Mabs A and B respectively, were established using CHOK1SV cells as the host cell and 
the GS Gene Expression System provided by Lonza Biologics (Slough, Berkshire, UK). 
These cell lines were selected in CD CHO medium (Life Technologies, Carlsbad, CA, 
USA) containing methionine sulfoximine. Chemically defined basal medium was 
developed for the fed-batch process by modifying the CD CHO medium with in-house 
proprietary supplements. This protein-free, chemically defined feed media developed in-
house were used for the fed-batch culture for this study. 
 
4.2.2.  Fed-batch culture 
Fed-batch cultures were performed using IgG-producing CHO cell line A and B. In-house 
serum-free basal and feed medium were used in these studies. Agitation was kept at speed 
which was determined to show the expected power per unit volume or kLa ratio. The 
temperature was kept at 37ºC. The pH was controlled by pure CO2 sparging and by the 
addition of 1.0M sodium carbonate. DO was controlled at 50% air saturation by aeration 
to headspace and, oxygen and air mixed gas aeration from sparger.  Small amount of 
sample was taken from reactor and DO, dCO2 and pH were measured by a blood gas 
analyzer (Rapidlab 348 blood gas analyzer (Bayer Corp., MA, USA)). Cell viability and 
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viable cell density were measured by Vi-CELL XR (Beckman Coulter, CA, USA). 
Glucose and lactate concentrations in the supernatant were determined with a BF-5 
bioanalyzer (Oji Scientific Instruments, Hyogo, Japan). After centrifugation, Mab 
concentration was measured using an HPLC system (Waters/mS, USA) with a UV 
detector and a POROS PA affinity column (Applied Biosystems/mA, USA). Specific 
growth and production rates were calculated according to previous report (19). 
 
4.3.  Results 
4.3.1.  Fed-batch culture using SS 200-L and 2000-L based on kLa ratio scale-
up 
In order to evaluate the agitation condition determined by the kLa ratio, fed-batch culture 
using 200-L and 2000-L SS bioreactor were carried out and dCO2 was evaluated during 
cultivation. Fed-batch cultivation was carried out for 16 days using Cell line B producing 
Mab-B. As shown in Figure 5, antibody concentration, viable cell density, and viability 
in 2000L cultivation showed the same tendency with 200L result. The antibody 
concentration reached about 5.5 g/L. Specific Mab production rate was 42  1.7 pg cell-1 
day-1 in 200-L scale and 49  0.9 pg cell-1 day-1 in 2000-L scale. The maximum viable 
cell density was obtained at 8 days of cultivation for the 2000-L scale, but at 10 days for 
the 200-L scale. On 200-L scale maximum viable cell density was about 14 x 106 cells/mL 
and on 2000-L scale maximum viable cell density was about 13 x 106 cells/mL, 
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respectively. Specific growth rate during day 1 to day 7 were 0.022 0.002 h-1 in 200-L 
scale and 0.022 0.002 h-1 in 2000-L scale respectively. However, dCO2 tended to be kept 
lower at the 2000-L scale and showed similar value at end of cultivation. When Cell line 
A was cultured based on P/V as shown in Figure 3, the dCO2 in the 200-L scale was lower 
throughout the cultivation. However, the agitation speed optimized based on the kLa ratio 
was set to 2000-L scale bioreactor, dCO2 showed the similar tendency during cultivation, 
especially at the end of the cell culture. At the end of the cell culture, dCO2 was 78 mmHg 
in 2000-L scale bioreactor process based on P/V and 57 mmHg in 200-L scale, 
respectively. On the other hands, lower dCO2 was observed in 2000-L scale bioreactor 
process optimized by kLa ratio from day 6 to day 16. At the end of the cell culture, dCO2 








Figure 5 Time course of cell line B cultivation under agitation conditions based on kLa 
ratio on 2000-L scale SS bioreactor. A: Mab concentration, B: Viable cells density, C: 




4.3.2.  Fed-batch culture result comparing SS 200-L bioreactor to single-use 
bioreactors scaled up based on kLa ratio 
The fed-batch culture was performed in the single-use bioreactor using the conditions 
determined by the agitation and aeration conditions determined by kLa ratio. In order to 
compare various types of single-use bioreactor, the agitation and aeration conditions for 
fed-batch culture was determined 100 rpm agitation for vendor A, 100 rpm for vendor B 


























































































according to the result of kLa ratio. Sparger type is open pipe in vendor A and drilled hole 
sparger for vendor B, and C. 
The agitation condition for 1000-L scale of vendor A are desirable at 65 rpm or more from 
the result of mixing time, but at 50 rpm from the result of kLa ratio. In previous result as 
shown in Figure 4, the mixing time greatly changed from 56 seconds to 34 seconds 
between 50 and 65 rpm. It is estimated that the mixing time of 1000-L scale of vendor A 
might be the same value as that of 200L SS bioreactor between 50 and 65 rpm conditions. 
Based on this assumption, we selected agitation speed for 55 rpm in 1000-L scale single 
use bioreactor of vendor A. 
Fed-batch cultures were performed using Cell line A producing Mab-A using 200-L scale 
stainless steel bioreactor, (control rpm,), 200-L scale single use vendor-A (100 rpm, open 
pipe type sparger), 200-L scale single use vendor-B (100 rpm, drilled hole type sparger), 
200-L scale single use vendor-C (210 rpm, additional constant nitrogen gas sparge at 
0.001vvm, drilled hole type sparger), and 1000-L scale single use bioreactor of vendor 
A(55 rpm, open pipe type sparger). Sixteen days of culture was performed and sampling 
was carried out daily during the culture period to measure viable cell density, viability, 
glucose and lactate concentrations (data not shown), and antibody concentration. Figure 
6 shows times courses of antibody concentration, viable cell density, viability, and dCO2. 
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Antibody concentration, viable cell density, and viability showed the similar trend among 
bioreactors. The maximum viable cell densities in all bioreactors were between 17 and 21 
x 106 cells/mL. Compared with cell culture experiment shown in Figure 3, the viability 
gradually decreased after day 12 of cultivation. Specific growth rate during day 1 to day 
7 were 0.021 0.003 h-1 200-L scale SS bioreactor, 0.020 0.002 h-1 in 200-L scale 
vendor-A 0.020 0.002 h-1 in vendor-B, 0.021 0.001 h-1 in 200-L scale vendor-C and 
0.019 0.002 h-1 in 1000-L scale vendor-A. The antibody concentration reached about 6 
g/L at the end of cultivation. Specific Mab production rate was 33  1.7 pg cell-1 day-1 in 
200-L scale SS bioreactor, 33  0.5 pg cell-1 day-1 in 200-L scale vendor-A, 35  05 pg 
cell-1 day-1 in vendor-B, 29  0.5 pg cell-1 day-1 in 200-L scale vendor-C and 35  1.8 pg 
cell-1 day-1 in 1000-L scale vendor-A. Among all fed-batch cultivation dCO2 gradually 







Figure 6 Time course of cell line A cultivation under the agitation conditions based on 
kLa ratio on single use bioreactors. A: Viable cells density, B: Viability, C: Mab 
concentration, D: dCO2. Symbols are 200-L scale stainless steel (closed circle), 200-L 
scale vendor-A (closed square), 200-L scale vendor-B (closed triangle), 200-L scale 
vendor-C (closed rhombus), and 1000-L scale vendor-A (open square). Regarding 200-L 
scale vendor-B, agitation speed was changed from 100 to 90 rpm (*1) and from 90 to 100 
rpm again (*2). 
The aeration and agitation conditions were 200-L scale stainless steel (Control rpm), 200-
L scale vendor-A (100 rpm, open pipe type sparger), 200-L scale vendor-B (100 rpm, 
drilled hole type sparger), 200-L scale vendor-C (210rpm, additional constant nitrogen 
gas sparge at 0.001vvm, drilled hole type sparger), and 1000-L scale vendor-A (55 rpm, 
open pipe type sparger). 
 
4.3.3.  Discussion 
The accumulation dCO2 at the end of the cultivation was only observed in the vendor B 
single-use bioreactor, but the time-course trend of the viable cell density was similar. It 


























































































200-L scale SS : ● 
200-L scale vendor-A: ■ 
200-L scale vendor-B: ▲ 
200-L scale vendor-C: ◆ 
1000-L scale vendor-A: □.  
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not be depressed by the antifoam agent addition might cause the dCO2 accumulation. The 
accumulation of foam seems to be related to the size of the aeration bubble, which is 
closely related to the shape of the sparger and the aspect ratio of the bioreactor. The dCO2 
accumulation was observed on day 13 of culture using vendor B bioreactor. To decrease 
dCO2, the agitation condition of vendor b bioreactor was changed from 100 rpm to 90 
rpm. And then, the aeration rate automatically increased in order to keep constant DO and 
dCO2 decreased. However, dCO2 dropped to lower level than those of other bioreactors 
cultivation at the time of sampling on the day 14 of culture, I changed the agitation rate 
to100 rpm until harvest time. The results of quality analysis of Mab A at the end of 
cultivation were shown in Table 6. Charge heterogeneity is important for safety and 
efficacy of therapeutic antibody (20). Aggregates may induce adverse immune response 
(21). Glycan profile also affects the ADCC activity, CDC activity and half-life in blood 
(22). Wang reported that galactosylation ratio in glycan profile was increased in low dCO2 
condition (23). In this fed-batch culture study all these results of quality analysis were 
similar in all bioreactors as shown in Table 6.
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pI : 9.49 9.49 9.49 9.50 9.49 
Acidic 
Species (%) : 
42.6 43.17 43.14 41.36 43.69 
Major 
Isoform (%) : 
53.7 53.4 53.4 54.4 52.9 
Basic Species 
(%) : 






 99 99 99 99 99 
% 
Aggregates : 
0.48 0.49 0.46 0.48 0.46 
Glycan profile 
GN1G0 (%) : 0.4 0.4 0.5 0.5 0.4 
G0 (%) : 4.9 4.9 5.6 5.7 5.1 
GN1G0F 
(%): 
0.1 0.1 0.1 0.1 0.1 
G0F (%) : 88.4 87.7 87.1 87.3 87.7 
Man5 (%) : 1.3 1.3 1.6 1.8 1.3 
G1F (%) : 2.3 2.4 2.0 2.6 2.1 
40 
 
P/V-based scale-up has the advantage of short process design time because the scale up 
procedure could be attained by calculation on the basis of bioreactor design. On the other 
hand, the kLa ratio-based scale-up requires experimental data for kLa (O2) and kLa (CO2) 
under various agitation and sparging conditions. However, it was suggested that it may 
be possible to construct a comparable scale up process with higher probability than P/V. 
In addition, kLa ratio-based scale-up could be applied for various single-use bioreactor 
scale-up, even their shape and blade type are not the same. In this research, this scale-up 
strategy was able to be used in two cell lines. And kLa may be estimated by computational 
fluid dynamics (24, 25). Therefore, it is considered to be a powerful tool for technology 
transfer to manufacturing site i.e., contract manufacturing organization (CMO) who are 
using various types of bioreactor. In early development stage of biopharmaceuticals, a 
period of process development is very limited. Under this circumstance, scale-up method 
based on P/V is suitable for quick process development. In contract, for development of 
late stage programs, it might be better to use kLa ratio scale-up for determination of 
agitation condition to construct robust process to achieve stable and reproducible dCO2 
trend. 
From the view point of performances of the bioreactor, I focused on the kLa ratio and used 
it for the scale-up factor. Both kLa(O2) and kLa(CO2) changed with increases of the 
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sparging rate and agitation speed. However, the effect of the sparging rate and agitation 
speed on kLa(O2) and kLa(CO2) value are not the same. CO2 in medium could be removed 
by oxygen gas sparging which supplied for DO control. The difference in kLa(O2) under 
various bioreactor operation causes the difference of aeration rate of oxygen, and also 
caused the difference of accumulation of CO2 in each cultivation. It was confirmed that 
accumulation of dCO2 did not occur at the determined agitation and aeration condition 
where the kLa ratio is similar to the bioreactor process in which dCO2 does not accumulate. 
In lower agitation condition, kLa ratio was higher as shown in Table 2 and Table 3 (e.g. 
0.49 in Conrol-6 agitation condition and 0.30 in Control+1 agitation condition with 
0.0085 vvm in SS 2000-L, 0.46 in 50 rpm and 0.28 in 80 rpm with 0.035 vvm in Vendor-
A 1000-L). However, in lower agitation condition, the mixing time could be delayed, 
causing non-uniform mixing in the bioreactor, affecting the cell culture performance. The 




Chapter 5.  Conclusion 
Biopharmaceuticals are now one of the main approaches to the various therapeutic area. 
More than half of top ten selling pharmaceutical drugs are biopharmaceuticals produced 
by bioprocess. Scale-up and scale-out method are major strategy to obtain production 
capability for bioprocess. Bioprocess scale-up in biopharmaceuticals production is 
important to produce drug substance keeping comparability of productivity and quality 
and reducing cost of goods.  
Several Mabs have been launched in the market and a lot of Mabs are developing now. 
Mabs have often been produced by batch or fed-batch culture process using CHO cells. 
Accompanying improvement of productivity, quality assurance, is required. In addition, 
production scales are expected to be increased with the development stage of 
pharmaceutical pipeline progresses and the manufacturing site changes. Quality 
equivalence (comparability) should be kept during these development stage and scale-up 
process to ensure efficacy and toxicity consistency.  
As various cell culture parameters, such as pH and temperature are known to affect a 
product quality such a glycan profile, and aggregation content, optimal culture conditions 
have been investigated using various cell lines and cell culture medium. It is also well 
known that the dCO2 also affects the product quality. However, since CO2 was produced 
from cells by cellular metabolism of TCA cycle, it is difficult to exactly control the dCO2 
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during cell culture and/or scale up processes. In this thesis, I compare the scale up factors 
obtained by calculation and by experiment. I evaluated both factors in view of cell growth, 
productivity and dCO2 trend. Advantage and disadvantage were discussed in this thesis. 
In Chapter 2, I focused on Power per unit volume (P/V) value for a scale-up factor 
obtained from the calculation. Fed-batch culture was conducted in 200-L and 2000-L 
scale SS bioreactor. The maximum viable cell density was about 20 x 106 cells/mL in both 
fed-batch culture. The viability gradually decreased after the 12th day of culture. The 
Mab concentration reached about 6 g/L at the time of harvest. dCO2 shifted around 60 
mmHg in the 200-L scale throughout the culture period, but it was kept at around 80 
mmHg on the 2000-L scale. dCO2 tended to be higher on the 2000-L than that on 200-L 
cultivation. Even the different dCO2 during cultivation, cell growth and the productivity 
were similar between 200-L and 2000-L cultivations. 
In Chapter 3, mixing time and kLa for a scale-up factor obtained from the experimental 
data. The mixing time was analyzed using pH measurement. The mixing time of the 200-
L scale SS bioreactor was 21 seconds under the control agitation condition. In the 2000-
L SS bioreactor, mixing time was 40 seconds under the agitation condition which was 
determined based on P/V. In the 2000-L SS bioreactor, mixing time was similar in the 
agitation conditions among control to control-6. The mixing time of single-use 
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bioreactors from vendor A, B, and C were also evaluated. Vendor A provided 200-L scale 
and 1000-L scale, and vendors B and C provided the 200-L scale. On the 200-L scale, the 
mixing time for vendor A reactor was about 30 seconds between 45 rpm and 100 rpm. 
The time for vendor B reactor was about 35 seconds at more than 100 rpm, and the time 
for vendor C reactor was less than 35 seconds at more than 210 rpm. From the results of 
mixing time and comparison with a SS bioreactor, it was estimated that the appropriate 
agitation range for 200-L single-use reactor was 45 rpm or more for vendor A, 100 rpm 
for vendor B and 210 rpm or more for vender C, respectively. 
In Chapter 4, the kLa ratio calculated by kLa(O2) and kLa(CO2) was evaluated for the scale-
up parameter of bioreactor. In order to evaluate the agitation condition determined by the 
kLa ratio, fed-batch culture using 200-L and 2000-L SS bioreactor were carried out and 
dCO2 was evaluated during cultivation. Mab concentration, viable cell density, and 
viability in 2000L cultivation showed the same tendency with 200 L result. The antibody 
concentration reached about 5.5 g/L in both scales. The agitation speed optimized based 
on the kLa ratio was set to 2000-L scale bioreactor. dCO2 showed the similar tendency 
during cultivation, especially at the end of the cell culture. Fed-batch cultures were 
performed using Cell line A producing Mab-A using 200-L scale stainless steel bioreactor, 
(control rpm,), 200-L scale single use vendor-A (100 rpm, open pipe type sparger), 200-
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L scale single use vendor-B (100 rpm, drilled hole type sparger), 200-L scale single use 
vendor-C (210 rpm, additional constant nitrogen gas sparge at 0.001vvm, drilled hole type 
sparger), and 1000-L scale single use bioreactor of vendor A (55 rpm, open pipe type 
sparger). Mab concentration, viable cell density, and viability showed the similar trend 
among bioreactors. The antibody concentration reached about 6 g/L at the end in all 
bioreactor cultivation. The cell culture performance and product quality at the end of the 
cultivation process were comparable for all tested SUBs.  
Through this research, all scale-up studies were achieved successfully. In the scale-up 
with P/V dCO2 were slightly higher in large scale. However, this accumulation didn’t 
have impact on productivity. The scale-up method to avoid accumulation of dCO2 was 
developed in this research. I concluded that the kLa ratio is a powerful scale-up factor 
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